121 related articles for article (PubMed ID: 32469160)
1. Characterization of patients with diabetes who were incidentally found to be glutamic acid decarboxylase autoantibody-positive by bridging-type enzyme-linked immunosorbent assay.
Kawasaki E; Fukuyama T; Uchida A; Sagara Y; Tamai H; Nakano Y; Tojikubo M; Hiromatsu Y; Koga N
J Diabetes Investig; 2020 Nov; 11(6):1507-1510. PubMed ID: 32469160
[TBL] [Abstract][Full Text] [Related]
2. Discrepancy of glutamic acid decarboxylase 65 autoantibody results between RSR radioimmunoassay and enzyme-linked immunosorbent assay in patients with type 1 diabetes is related to autoantibody affinity.
Kawasaki E; Okada A; Uchida A; Fukuyama T; Sagara Y; Nakano Y; Tamai H; Tojikubo M; Koga N
J Diabetes Investig; 2019 Jul; 10(4):990-996. PubMed ID: 30582775
[TBL] [Abstract][Full Text] [Related]
3. Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes.
Kawasaki E; Awata T; Ikegami H; Imagawa A; Oikawa Y; Osawa H; Katsuki T; Kanatsuna N; Kawamura R; Kozawa J; Kodani N; Kobayashi T; Shimada A; Shimoda M; Takahashi K; Chujo D; Tsujimoto T; Tsuchiya K; Terakawa A; Terasaki J; Nagasawa K; Noso S; Fukui T; Horie I; Yasuda K; Yasuda H; Yanai H; Hanafusa T; Kajio H;
J Diabetes Investig; 2024 Jul; 15(7):835-842. PubMed ID: 38451108
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic characteristics of people with type 1 diabetes who have discrepancies in titers of anti-glutamic acid decarboxylase antibody measured by radioimmunoassay and enzyme-linked immunosorbent assay.
Takagi S; Miura J; Hoshina S; Uchigata Y; Babazono T
J Diabetes Investig; 2020 Mar; 11(2):356-362. PubMed ID: 31267698
[TBL] [Abstract][Full Text] [Related]
5. Actual condition survey regarding mismatch of measurements between radioimmunoassay and enzyme-linked immunosorbent assay tests for anti-glutamic acid decarboxylase antibody in real-world clinical practice.
Oikawa Y; Kondo T; Shimada A; Seino Y; Kitaoka M
J Diabetes Investig; 2019 May; 10(3):685-689. PubMed ID: 30307126
[TBL] [Abstract][Full Text] [Related]
6. Zinc transporter 8 autoantibodies complement glutamic acid decarboxylase and insulinoma-associated antigen-2 autoantibodies in the identification and characterization of Japanese type 1 diabetes.
Kawasaki E; Oikawa Y; Okada A; Kanatsuna N; Kawamura T; Kikuchi T; Terasaki J; Miura J; Ito Y; Hanafusa T
J Diabetes Investig; 2020 Sep; 11(5):1181-1187. PubMed ID: 32175683
[TBL] [Abstract][Full Text] [Related]
7. Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.
Yamamura S; Fukui T; Mori Y; Hayashi T; Yamamoto T; Ohara M; Fukase A; Sasamori H; Kobayashi T; Hirano T
J Diabetes Investig; 2019 Nov; 10(6):1480-1489. PubMed ID: 30919585
[TBL] [Abstract][Full Text] [Related]
8. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults.
Li X; Yang L; Zhou Z; Huang G; Yan X
Chin Med J (Engl); 2003 Nov; 116(11):1728-32. PubMed ID: 14642146
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea.
Kim CS; Nam JH; Nam JS; Park JS; Kang ES; Ahn CW; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
Metabolism; 2006 Aug; 55(8):1107-12. PubMed ID: 16839848
[TBL] [Abstract][Full Text] [Related]
10. Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up.
Huang G; Yin M; Xiang Y; Li X; Shen W; Luo S; Lin J; Xie Z; Zheng P; Zhou Z
Diabetes Metab Res Rev; 2016 Sep; 32(6):615-22. PubMed ID: 26787598
[TBL] [Abstract][Full Text] [Related]
11. Levels of cytokines and GADA in type I and II diabetic patients.
Amin K; Qadr SH; Hassan Hussein R; Ali KM; Rahman HS
Prim Care Diabetes; 2020 Feb; 14(1):61-67. PubMed ID: 31014937
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel ultrasensitive enzyme immunoassay for human glutamic acid decarboxylase 65 antibody.
Numata S; Katakami H; Inoue S; Sawada H; Hashida S
Ann Clin Biochem; 2016 Jul; 53(Pt 4):495-503. PubMed ID: 26384362
[TBL] [Abstract][Full Text] [Related]
13. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus.
Arikan E; Sabuncu T; Ozer EM; Hatemi H
J Diabetes Complications; 2005; 19(5):254-8. PubMed ID: 16112499
[TBL] [Abstract][Full Text] [Related]
14. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.
Turner R; Stratton I; Horton V; Manley S; Zimmet P; Mackay IR; Shattock M; Bottazzo GF; Holman R
Lancet; 1997 Nov; 350(9087):1288-93. PubMed ID: 9357409
[TBL] [Abstract][Full Text] [Related]
15. Slowly progressive insulin-dependent (type 1) diabetes positive for anti-GAD antibody ELISA test may be strongly associated with a future insulin-dependent state.
Oikawa Y; Tanaka H; Uchida J; Atsumi Y; Osawa M; Katsuki T; Kawai T; Shimada A
Endocr J; 2017 Feb; 64(2):163-170. PubMed ID: 27760891
[TBL] [Abstract][Full Text] [Related]
16. Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study.
Vigo A; Duncan BB; Schmidt MI; Couper D; Heiss G; Pankow JS; Ballantyne CM
Braz J Med Biol Res; 2007 Jul; 40(7):933-41. PubMed ID: 17653446
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of anti-glutamic acid decarboxylase antibody-positive fulminant type 1 diabetes.
Saito D; Oikawa Y; Mizutani G; Inoue K; Hatano M; Inoue I; Noda M; Shimada A
Endocr J; 2019 Apr; 66(4):329-336. PubMed ID: 30760658
[TBL] [Abstract][Full Text] [Related]
18. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.
Törn C; Landin-Olsson M; Ostman J; Scherstén B; Arnqvist H; Blohmé G; Björk E; Bolinder J; Eriksson J; Littorin B; Nyström L; Sundkvist G; Lernmark A
Diabetes Metab Res Rev; 2000; 16(6):442-47. PubMed ID: 11114103
[TBL] [Abstract][Full Text] [Related]
19. Single-tube test for autoantibodies to glutamic acid decarboxylase and proinsulin as first-line screening for autoimmunity in adult-onset diabetic patients.
Valdez SN; Villalba A; Iacono RF; Poskus E
Clin Immunol; 2004 Dec; 113(3):241-7. PubMed ID: 15507388
[TBL] [Abstract][Full Text] [Related]
20. GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.
Dittler J; Seidel D; Schenker M; Ziegler AG
Diabetes; 1998 Apr; 47(4):592-7. PubMed ID: 9568692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
